American Association for Cancer Research
Browse
00085472can151787-sup-147859_1_supp_0_w1msmq.docx (25.04 kB)

Supplementary Table S2 from Mutational Landscape of Aggressive Prostate Tumors in African American Men

Download (25.04 kB)
journal contribution
posted on 2023-03-31, 00:00 authored by Karla J. Lindquist, Pamela L. Paris, Thomas J. Hoffmann, Niall J. Cardin, Rémi Kazma, Joel A. Mefford, Jeffrey P. Simko, Vy Ngo, Yalei Chen, Albert M. Levin, Dhananjay Chitale, Brian T. Helfand, William J. Catalona, Benjamin A. Rybicki, John S. Witte

Individual patient Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) scores and test results, with and without copy-neutral losses.

Funding

The Urological Research Foundation

the UCSF Goldberg-Benioff Program in Cancer Translational Biology

History

ARTICLE ABSTRACT

Prostate cancer is the most frequently diagnosed and second most fatal nonskin cancer among men in the United States. African American men are two times more likely to develop and die of prostate cancer compared with men of other ancestries. Previous whole genome or exome tumor-sequencing studies of prostate cancer have primarily focused on men of European ancestry. In this study, we sequenced and characterized somatic mutations in aggressive (Gleason ≥7, stage ≥T2b) prostate tumors from 24 African American patients. We describe the locations and prevalence of small somatic mutations (up to 50 bases in length), copy number aberrations, and structural rearrangements in the tumor genomes compared with patient-matched normal genomes. We observed several mutation patterns consistent with previous studies, such as large copy number aberrations in chromosome 8 and complex rearrangement chains. However, TMPRSS2-ERG gene fusions and PTEN losses occurred in only 21% and 8% of the African American patients, respectively, far less common than in patients of European ancestry. We also identified mutations that appeared specific to or more common in African American patients, including a novel CDC27-OAT gene fusion occurring in 17% of patients. The genomic aberrations reported in this study warrant further investigation of their biologic significant role in the incidence and clinical outcomes of prostate cancer in African Americans. Cancer Res; 76(7); 1860–8. ©2016 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC